| Filed On | Filing |
|---|---|
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Net income of $0.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.01 |
| 18 Sep 2026 | SCHEDULE 13G/A |
| 01 Sep 2026 | SCHEDULE 13G/A |
| 28 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 |
Form 4: Beer Marc D, Director
Bought 115,950 shares ($177K) · Bought 16,000 shares ($24.8K) |
| 07 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Net loss of $(7.4) million and diluted loss per share attributable to biote Corp. stockholders of $(0.23), compared to net income of $3.9 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10 in the sec... |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 17 Jun 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 16 Jun 2026 |
Form 4: Peterson Robert Charles, Director
Granted 206,746 Stock Options (Right to buy) |
| 10 Jun 2026 |
Form 4: Christensen Bret, Director
Granted 130,000 Stock Option (Right to Buy) |
| 10 Jun 2026 |
Form 4: Beer Marc D, Director
Granted 114,157 Employee Stock Option (Right to Buy) |
| 02 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
IRVING, TX–(BUSINESS WIRE)–May 28, 2026–Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced that Bob Peterson, Chief Fi... |
| 18 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 12, 2026, biote Corp., a Delaware corporation (the “Company”), held its 2026 annual meeting of stockholders (the “Annual Meeting”). |
| 14 May 2026 |
Form 4: Heyer Andrew R, Director
Granted 35,259 Deferred Settlement RSU · Granted 130,000 Stock Option (Right to Buy) |
| 13 May 2026 |
Form 4: Morris Debra L, Director
Received 21,407 shares by exercise or conversion · Granted 39,036 Deferred Settlement RSU · Granted 130,000 Stock Option (Right to Buy) |
| 13 May 2026 |
Form 4: Cone Stephen Mark, Director
Granted 31,481 Deferred Settlement RSU · Granted 130,000 Stock Option (Right to Buy) |
| 13 May 2026 |
Form 4: Jacoby Dana Lynn, Director
Granted 37,777 Deferred Settlement RSU · Granted 130,000 Stock Option (Right to Buy) |
Loading...